No Data
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
US Manufacturing Index Rises To 43, Highest Since 2020
Intra-Cellular Therapies(ITCI.US) Officer Sells US$3.69 Million in Common Stock
Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 3.7 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $Intra-Cellular Therapies(ITCI.US)$ Officer Halstead Michael intends to sell 41,583 shares of its common stock on Nov 12, with a total market value of approximately $3.
